Saturday, 31 October 2026European Markets

FINATIS Stock Went Down By Over 27% In The Last 21 Sessions

Loading stream...

finatis (fnts.pa), a french food distribution company, experienced an alarming decline during recent trading sessions. over just 21 days, its stock price declined 27.36% from eur4.02 to eur2.92, falling after five consecutive sessions of losses; even as cac 40 index posted an incremental gain of 0.13 percentage points.

about finatis

finatis is a subsidiary of euris sas that operates food markets and sports equipment stores in france and latin america. however, its unimpressive earnings per share (eps) over the last twelve months (negative eur24.26) may have investors questioning its financial viability.

trading volume and investor activity

notably, the stock's last reported trading volume was 752, almost twice its average trading volume of 113. this may reflect increased investor activity or interest during times of extreme price fluctuation.

earnings per share and investor sentiments

reviewing these developments requires financial literacy surrounding eps (earnings per share). this figure represents the proportion of profit allocated per outstanding share of common stock; therefore a negative eps like finatis may be seen as a warning sign and coupled with their stock price decline may signal investor disillusionment with its health.

more news about finatis (fnts.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com